Cargando…

Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15

Under physiological conditions, the trans-presentation of interleukin-15 (IL-15) by the IL-15 receptor α on the cell surface allows to confine and tune the IL-15-mediated immune responses. Therefore, targeting strategies that mimic this situation at the tumor sites appear especially promising for an...

Descripción completa

Detalles Bibliográficos
Autor principal:	Müller, Dafne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2012
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494650/ https://www.ncbi.nlm.nih.gov/pubmed/23170284 http://dx.doi.org/10.4161/onci.20824

Ejemplares similares

Targeting of IL-2 to cytotoxic lymphocytes as an improved method of cytokine-driven immunotherapy
por: Lazear, Eric, et al.
Publicado: (2017)

IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Expand to shield: IL-15 and in situ lymphocytic proliferation
por: Bindea, Gabriela, et al.
Publicado: (2021)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
por: Kim, Peter S, et al.
Publicado: (2014)

Targeting dendritic cells in situ for breast cancer immunotherapy
por: Wang, Bei
Publicado: (2012)

Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?
por: Swarbrick, Alexander, et al.
Publicado: (2013)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells
por: Todaro, Matilde, et al.
Publicado: (2013)

DKK1 as a novel target for myeloma immunotherapy
por: Qian, Jianfei, et al.
Publicado: (2012)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection
por: Pilones, Karsten A., et al.
Publicado: (2020)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Strong emerging rationale for combining oncogene-targeted agents with immunotherapy
por: Yang, Yan, et al.
Publicado: (2013)

Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression
por: Smyth, Mark J, et al.
Publicado: (2014)

Antagonizing the innate pattern recognition receptor CD204 to improve dendritic cell-targeted cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2012)

Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy
por: Rudqvist, Nils-Petter, et al.
Publicado: (2023)

Dual targeting of CD137 co-stimulatory and PD-1 co-inhibitory molecules for ovarian cancer immunotherapy
por: Wei, Huafeng, et al.
Publicado: (2014)

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4(+) and CD8(+) T cells
por: Tomita, Yusuke, et al.
Publicado: (2013)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Chemokine-enhanced DNA vaccination in cancer immunotherapy
por: Igoucheva, Olga, et al.
Publicado: (2013)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Pharmacological DNA demethylation: Implications for cancer immunotherapy
por: Roulois, David, et al.
Publicado: (2015)

FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012)

New insights into the role of NK cells in cancer immunotherapy
por: Salagianni, Maria, et al.
Publicado: (2012)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

Cancer immunotherapy with exosomes requires B-cell activation
por: Näslund, Tanja I, et al.
Publicado: (2013)

The immune landscape of human tumors: Implications for cancer immunotherapy
por: Bindea, Gabriela, et al.
Publicado: (2014)

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy
por: Shen, Li, et al.
Publicado: (2012)

A novel strategy for modulation of MDSC to enhance cancer immunotherapy
por: Ghansah, Tomar
Publicado: (2012)

Of microspheres and microbes: A double-hit strategy for cancer immunotherapy
por: Brinkhoff, Benjamin, et al.
Publicado: (2014)

Immunotherapy of HPV-associated head and neck cancer: Critical parameters
por: Nizard, Mevyn, et al.
Publicado: (2013)

Engineering Grp170-based immune modulators for cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2013)

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
por: Workenhe, Samuel T, et al.
Publicado: (2013)

Inhibition of RANK signaling as a potential immunotherapy in breast cancer
por: Gómez-Aleza, C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_89maafla1j3kmprun7n5t62a56